FY2025 EPS Estimates for Inventiva Cut by HC Wainwright

Key Points

• HC Wainwright has cut its FY2025 earnings estimates for Inventiva S.A. to ($2.48) per share, down from a previous estimate of ($1.44).
• Despite the lowered earnings outlook, HC Wainwright maintains a "Buy" rating on Inventiva, with a price target of $24.00 for the stock.
• Six investment analysts currently rate Inventiva as a Buy, indicating a consensus rating of "Moderate Buy" with a consensus price target of $16.14.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings estimates for Inventiva in a report issued on Thursday, October 9th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($2.48) for the year, down from their prior estimate of ($1.44). HC Wainwright has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Inventiva's current full-year earnings is ($2.08) per share. HC Wainwright also issued estimates for Inventiva's FY2026 earnings at ($2.72) EPS, FY2027 earnings at ($3.42) EPS, FY2028 earnings at ($0.94) EPS and FY2029 earnings at $1.33 EPS.

IVA has been the topic of a number of other research reports. Piper Sandler began coverage on shares of Inventiva in a report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price target on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Guggenheim raised their target price on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Inventiva in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.14.

Inventiva Stock Performance

Shares of IVA stock opened at $4.55 on Monday. The company has a 50 day moving average of $5.13 and a 200-day moving average of $3.95. Inventiva has a 12-month low of $1.68 and a 12-month high of $6.55.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning bought a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,000 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.